BIOTECH

Stay updated with the latest advancements in biotechnology, genetics, and medical research. Explore innovations shaping the future of healthcare and science!

Shionogi’s RSV Antiviral Reduces Viral Load In Phase 2 Trial of Adults

Shionogi’s Respiratory Syncytial Virus (RSV) Antiviral has proven its ability to reduce viral load in phase 2 trials of adults. The study shows that 114 healthy adults were implanted with the virus and then given the antiviral, dubbed S-337395, or placebo for five days. Individuals who were treated with S-337395 showed a statistically significant reduction in viral load as compared to the placebo group. The Japanese biopharma singled out the…